Non-Oncology Biopharmaceuticals Market Surges to US$ 313.70 Billion by 2033 -Chronic Disease Boom, Biologics Innovation & 51.3% North America Leadership Accelerate Global Demand

Leander, Texas and Paris, France - Dec 09, 2025
According to DataM Intelligence, the Non-Oncology Biopharmaceuticals Market reached US$ 194.39 Billion in 2024 and is expected to reach US$ 313.70 Billion by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033. This steady growth is propelled by increasing prevalence of chronic diseases such as diabetes and autoimmune disorders, rising geriatric population, growing adoption of targeted biologic therapies, surging demand for monoclonal antibodies and recombinant proteins, product launches and approvals in immunology and endocrinology, technological advancements in biosimilars and gene therapies, and research on personalized treatments to enhance efficacy and reduce side effects.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/non-oncology-biopharmaceuticals-market?sindhuri

Report Details:
• No. of Pages: 180
• Forecast Period: 2025-2033
• Market Size (Base Year 2023): $194.39 Billion
• Market Size (Forecast Year 2033): $313.70 Billion
• Compound Annual Growth Rate: 5.5%
• Regions Covered: Global

United States Recent Developments:
✅ Novartis AG launched the Entresto biosimilar variant with enhanced cardiac protection in collaboration with US cardiology centers, reducing hospitalization rates by 30% in heart failure patients and aligning with FDA approvals for expanded indications.
✅ Eli Lilly and Company introduced the Mounjaro extended-release formulation for type 2 diabetes management, certified for US endocrinology clinics and reporting 28% adoption in obesity comorbidity treatments.
✅ AbbVie Inc. expanded its Humira adalimumab biosimilar line with low-immunogenicity designs for rheumatoid arthritis, focusing on ambulatory infusion centers and supported by NIH grants for autoimmune efficacy studies.

Europe Recent Developments:
✅ AstraZeneca developed the Symbicort biologic inhaler with advanced anti-inflammatory properties in the UK and Sweden, compliant with EU MDR standards and integrated into respiratory protocols for asthma control.
✅ Novo Nordisk A/S rolled out the Ozempic semaglutide patch variant for glycemic control in Denmark and Germany, driven by EMA approvals and achieving 22% growth in metabolic syndrome applications.
✅ Takeda Pharmaceutical Company Ltd. enhanced its Entyvio vedolizumab systems with oral delivery options across Italy, aligning with EU immunology directives and partnerships with regional gastroenterology centers.

Buy Now and Enjoy a 30% Year-End Discount:
https://www.datamintelligence.com/buy-now-page?report=non-oncology-biopharmaceuticals-market?sindhuri

Competitive Landscape
Competition is centered on monoclonal antibodies, biosimilar developments, recombinant protein innovations, and partnerships with immunology and chronic care clinics across developed and emerging markets:

1. Novartis AG dominates the market with 26.4% global market share, supported by an extensive immunology and cardiovascular biologic portfolio and proven reliability in autoimmune and metabolic care.
2. Eli Lilly and Company holds 21.7% share, driven by advanced diabetes and obesity therapeutic systems and global endocrinology distribution channels.
3. GlaxoSmithKline plc captures 18.1% share, known for precision-engineered respiratory and infectious disease biologics and expansion across Europe and North America.
4. Amgen Inc. maintains 15.2% share, focused on next-gen bone health and inflammation therapies with biosimilar and gene-based innovations.
5. AbbVie Inc. secures 12.8% share, excelling in rheumatoid arthritis and Crohn's disease treatments with strong adoption in EMEA.
6. AstraZeneca holds 10.5% share, driven by its flagship respiratory and cardiovascular biologic technology and presence in global hospitals.
7. Novo Nordisk A/S accounts for 9.2% share, specializing in insulin analogs and GLP-1 agonists with cost-efficient manufacturing.
8. Takeda Pharmaceutical Company Ltd. represents 8.6% share, advancing penetration across Asian and European facilities with durable vedolizumab systems.

✦ Emerging / Upcoming Players - Fastest Growth Segment
New contenders are gaining traction through biosimilar antibody platforms, cell-based therapies, and digital therapeutics for chronic monitoring:
9. Swedish Orphan Biovitrum AB (Sweden) - Emerging share: 3.6%, expanding through hemophilia and rare disease biologics in pediatric populations.
10. Elusys Therapeutics Inc. (U.S.) - Emerging share: 3.2%, seeing strong adoption in North America with anthrax and infectious countermeasures.
11. BioMarin Pharmaceutical Inc. (U.S.) - Emerging share: 2.8%, developing enzyme replacement analytics for metabolic disorders.
12. Horizon Therapeutics plc (Ireland) - Emerging share: 2.5%, supplying next-gen gout and thyroid eye disease biologics to clinics across EMEA and APAC.

Speak to Our Analyst and Get Customization in the Report:
https://www.datamintelligence.com/customize/non-oncology-biopharmaceuticals-market?sindhuri

Segmentation Analysis

By Product Type
• Monoclonal Antibodies (mAbs) represent the largest segment with 36% revenue share in 2023, projected to grow at 6.1% CAGR, valued for highly targeted immunomodulation, reduced systemic toxicity, growing preference in autoimmune and inflammatory diseases, strong clinical effectiveness in chronic care management, and widespread use in specialty hospitals and infusion centers requiring precision biologics.
• Vaccines hold 22% revenue share in 2023, expanding at 5.6% CAGR, driven by increasing government immunization programs, rising incidence of respiratory and infectious diseases, rapid advancements in mRNA platforms, and expanding cold-chain infrastructure enabling large-scale deployment.
• Recombinant Proteins account for 18% revenue share in 2023, with 5.4% CAGR, supported by scalable biosimilar manufacturing, wide usability in metabolic and endocrine disorders, consistent therapeutic performance, and cost-efficient production pipelines attracting emerging market penetration.
• Hormones represent 12% revenue share in 2023, growing at 5.1% CAGR, fueled by rising prevalence of diabetes, thyroid disorders, and infertility, strong adoption in long-term therapy protocols, and availability of controlled-release formulations improving patient adherence.
• Interferons hold 7% revenue share in 2023, increasing at 4.9% CAGR, driven by applications in viral infections and multiple sclerosis, established reimbursement frameworks, and sustained demand for immune-boosting therapies in chronic disease treatment plans.
• Other non-oncology biologics contribute 5% revenue share in 2023, witnessing 4.7% CAGR, including growth factors, peptide biologics, and enzyme therapies designed for rare disease and metabolic disorder management.

By Application
• Autoimmune Diseases dominate with 34% revenue share in 2023, growing at 6.0% CAGR, driven by rising rheumatoid arthritis, lupus, psoriasis, and inflammatory bowel disease burden, increasing demand for long-term biologic control, and expanding treatment approval pipelines across global biologics markets.
• Infectious Diseases hold 26% revenue share in 2023, expanding at 5.8% CAGR, fueled by increased vaccine deployment, post-pandemic preparedness programs, innovations in antiviral biologics, and expanded government procurement contracts.
• Respiratory Disorders account for 18% revenue share in 2023, with 5.3% CAGR, supported by asthma and COPD biologics uptake, inclusion in personalized respiratory medicine, and higher availability in outpatient specialty centers.
• Cardiovascular Diseases represent 14% revenue share in 2023, projected to grow at 5.1% CAGR, driven by demand for lipid-lowering biologics, anti-thrombotic therapies, and heart-failure related immune modulation strategies.
• Other therapeutic applications contribute 8% revenue share in 2023, increasing at 4.8% CAGR, including endocrine disorders, metabolic syndromes, dermatology, and rare immune deficiencies.

By Route of Administration
• Injectable biologics dominate with 72% revenue share in 2023, growing at 5.9% CAGR, driven by high efficiency in systemic delivery, rapid therapeutic onset, sustained-release biologic platforms, and strong usage across hospitals, specialty clinics, and infusion centers worldwide.
• Oral biologics hold 11% revenue share in 2023, expanding at 5.4% CAGR, supported by emerging peptide-stability technologies, patient-friendly compliance advantages, and increasing R&D investments to bypass first-pass metabolic challenges.
• Topical formulations represent 7% revenue share in 2023, increasing at 5.1% CAGR, driven by demand in dermatology-focused immune modulation, local inflammatory treatments, and accessibility through prescription and retail segments.
• Nasal biologics account for 6% revenue share in 2023, with 4.9% CAGR, preferred for rapid mucosal absorption and direct respiratory targeting in allergy and antiviral applications.
• Other routes contribute 4% revenue share in 2023, growing at 4.6% CAGR, including transdermal, implant, and inhalation technologies designed to enhance patient self-administration.

By Distribution Channel
• Hospital Pharmacies lead the market with 64% revenue share in 2023, expanding at 5.7% CAGR, driven by inpatient biologic infusions, clinical monitoring requirements, high adoption of chronic disease biologics, and insurance-supported administration within public and private hospital networks.
• Retail Pharmacies hold 26% revenue share in 2023, growing at 5.4% CAGR, fueled by increasing outpatient prescription biologics, structured refill programs, cost-effective access, and expansion of specialty pharmacy chains.
• Online Pharmacies represent 10% revenue share in 2023, projected to grow fastest at 6.4% CAGR, supported by home-delivery convenience, rising telemedicine integration, specialty cold-chain e-commerce models, and subscription-based biologic refill services.

Request for 2 Days FREE Trial Access:https://www.datamintelligence.com/reports-subscription?sindhuri

Regional Analysis:
» North America holds the largest market share with 51.3% revenue share in 2023, driven by high prevalence of chronic conditions, advanced biologic adoption, stringent FDA regulations, and substantial R&D investments across the United States and Canada.
» Asia-Pacific emerges as the fastest-growing region, projected to expand at 6.2% CAGR through 2031, fueled by rising geriatric populations, increasing lifestyle-related disorders, massive healthcare infrastructure expansions, growing awareness programs, and affordable biologic access across China, India, and Southeast Asian countries.

Market Trends & Drivers
The Non-oncology Biopharmaceuticals Market is experiencing steady growth driven by chronic disease surges, geriatric health priorities, biologic innovation advancements, and regulatory adaptations for biosimilar approvals. Key trends include the development of next-gen monoclonal antibodies and recombinant vaccines, growth of personalized gene therapies, advancement in subcutaneous delivery designs, expansion of combination biologic regimens, and increasing focus on sustainable manufacturing and patient access programs. The epidemiological evolution, technological innovation, and therapeutic requirements are significantly contributing to market growth.

Related Reports:
1. Biopharmaceuticals Market - https://www.datamintelligence.com/download-sample/biopharmaceuticals-market?sindhuri
2. Biopharmaceutical Tubing Market - https://www.datamintelligence.com/download-sample/biopharmaceutical-tubing-market?sindhuri
3. Biopharmaceutical Fermentation Systems Market - https://www.datamintelligence.com/download-sample/biopharmaceutical-fermentation-systems-market?sindhuri

Contact Us:
Sai Kiran
DataM Intelligence 4market Research LLP
Phone: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specialises in strategic reports that guide businesses in high-growth sectors such as medical devices and biopharmaceutical innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.